A profile of GeneVentiv’s origins, programs and development strategy in North Carolina’s gene therapy ecosystem.
North Carolina Biotechnology Center profiled GeneVentiv’s development of gene therapies for hemophilia and Pompe disease, including the company’s licensing of technologies from UNC-Chapel Hill and Duke University and the role of North Carolina’s life-sciences ecosystem in its growth.